Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

por Qiyi Zhang, Qiyi Zhang, Xingyu Liu, Xingyu Liu, Shumei Wei, Lufei Zhang, Lufei Zhang, Yang Tian, Yang Tian, Zhenzhen Gao, Zhenzhen Gao, Ming Jin, Ming Jin, Sheng Yan, Sheng Yan
Publicado 2021